Epoprostenol for Injection in Pulmonary Arterial Hypertension
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
This is a prospective, multi-center, open-label, randomized, Phase IV exploratory study
comparing safety, tolerability, pharmacokinetics, and effectiveness of ACT-385781A and Flolan
(epoprostenol sodium) in patients with pulmonary arterial hypertension who are naïve to
injectable prostanoid treatment and in need of such treatment. Approximately 30 patients from
8 U.S. clinical sites will be randomized to receive either ACT-385781A or Flolan (2:1
respectively) for 28 days of treatment.